Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 6/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25449 | 0.89 | MAPK1 (0.57) | HPGDMAPK1NPC1POLBRAB9A | |
| SCHEMBL4755850 | 0.83 | MAPK1 (0.51) | HPGDMAPK1NPC1POLBRAB9A | |
| SCHEMBL6351798 | 0.83 | MAPK1 (0.43) | HPGDMAPK1NPC1POLBRAB9A | |
| SCHEMBL6166312 | 0.83 | HPGD (0.46) | HPGDMAPK1KMT2AMEN1L3MBTL1 | |
| SCHEMBL6722955 | 0.76 | HPGD (0.46) | HPGDMAPK1NPC1POLBRAB9A | |
| SCHEMBL16077518 | 0.75 | HPGD (0.54) | HPGDMAPK1POLBRAB9AKMT2A | |
| SCHEMBL14019191 | 0.74 | MAPK1 (0.50) | HPGDMAPK1NPC1POLBRAB9A | |
| SCHEMBL14688254 | 0.73 | HPGD (0.46) | HPGDMAPK1NPC1POLBRAB9A | |
| SCHEMBL3827239 | 0.73 | POLB (0.48) | HPGDNPC1POLBRAB9AKMT2A | |
| SCHEMBL15981916 | 0.72 | HPGD (0.52) | HPGDMAPK1KMT2AL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239808-A1 | Active substances for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occur | TRANSMIT GESELLSCHAFT FUR TECHNOLOGIETRANSFER MBH (DE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239808-A1 | Active substances for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occur | PRNP, APP, MAPT | HPGD 1476/4885MAPK1 2492/4885NPC1 945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.